153,000 Shares in Gamida Cell Ltd. (NASDAQ:GMDA) Purchased by FNY Investment Advisers LLC
FNY Investment Advisers LLC acquired a new position in shares of Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 153,000 shares of the company’s stock, valued at approximately $197,000. FNY Investment Advisers LLC owned about 0.26% of Gamida Cell at the end of the most recent quarter.
→ Buy THIS stock before Taiwan is attacked (From Behind the Markets)
Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Gamida Cell by 2.2% in the 3rd quarter. BlackRock Inc. now owns 459,683 shares of the company’s stock worth $731,000 after acquiring an additional 10,092 shares during the last quarter. Virtu Financial LLC grew its stake in shares of Gamida Cell by 57.6% in the third quarter. Virtu Financial LLC now owns 31,922 shares of the company’s stock valued at $51,000 after buying an additional 11,667 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Gamida Cell by 539.0% in the first quarter. Bank of America Corp DE now owns 15,214 shares of the company’s stock valued at $63,000 after buying an additional 12,833 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Gamida Cell by 14.3% in the third quarter. Victory Capital Management Inc. now owns 114,569 shares of the company’s stock valued at $182,000 after buying an additional 14,305 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Gamida Cell in the second quarter valued at $42,000. 56.19% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC dropped their price objective on Gamida Cell from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 22nd.
Gamida Cell Stock Down 3.2 %
Shares of NASDAQ:GMDA traded down $0.05 during trading on Friday, hitting $1.50. The company’s stock had a trading volume of 277,213 shares, compared to its average volume of 567,001. The business has a 50 day moving average price of $1.54 and a two-hundred day moving average price of $1.69. The company has a market capitalization of $111.57 million, a PE ratio of -1.18 and a beta of 1.67. The company has a debt-to-equity ratio of 5.31, a quick ratio of 2.76 and a current ratio of 2.76. Gamida Cell Ltd. has a fifty-two week low of $1.10 and a fifty-two week high of $4.72.
Gamida Cell Profile
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies.
Featured Stories
Want to see what other hedge funds are holding GMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gamida Cell, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Gamida Cell wasn’t on the list.
While Gamida Cell currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
